IGHA1 and IgA glomerulonephritis: In a RCT of 34 patients with IgA nephropathy, rituximab failed to affect proteinuria, kidney function, serum levels of Gd-IgA1, or antibodies against Gd-IgA1, despite adequate depletion of CD20(+) B cells.65 These results imply that the cells pivotal for Gd-IgA1 and anti–Gd-IgA1 antibody formation may be CD20(−) and thus unaffected by rituximab.